Van ECK Associates Corp Has $16.93 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Van ECK Associates Corp decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 57,399 shares of the biopharmaceutical company’s stock after selling 3,539 shares during the period. Van ECK Associates Corp’s holdings in Alnylam Pharmaceuticals were worth $16,925,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ALNY. Ashton Thomas Private Wealth LLC acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $26,000. Allspring Global Investments Holdings LLC raised its stake in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Friedenthal Financial bought a new position in Alnylam Pharmaceuticals during the third quarter worth $51,000. Altitude Crest Partners Inc. bought a new position in Alnylam Pharmaceuticals during the first quarter worth $30,000. Finally, Farther Finance Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 95.4% in the third quarter. Farther Finance Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 103 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

ALNY has been the subject of a number of analyst reports. Bank of America lifted their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. Scotiabank upped their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Finally, Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $294.50.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $265.29 on Wednesday. The company has a market cap of $34.22 billion, a P/E ratio of -101.26 and a beta of 0.39. The stock has a fifty day moving average price of $274.33 and a 200 day moving average price of $228.73. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the previous year, the business earned $1.15 earnings per share. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.